Stock Events

Stock Events

BioAffinity Technologies 

$15.27
52
+$2.49+19.48% Friday 20:00
-$4.91-32.15%Friday 23:59After hours

Statistics

Day High
15.4
Day Low
15.07
52W High
202.5
52W Low
4.56
Volume
49,920
Avg. Volume
-
Mkt Cap
9.04M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-31.5
-21.05
-10.6
-0.15
Expected EPS
-31.5
Actual EPS
N/A

Financials

-241.97%Profit Margin
Unprofitable
2021
2022
2023
2024
2025
6.16MRevenue
-14.91MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BIAF. It's not an investment recommendation.
NVIDIA
10
NVDA
AMD
10
AMD
Tesla
8
TSLA
Hims & Hers Health
7
HIMS

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap21.67B
Guardant Health, Inc. specializes in liquid biopsy tests, which overlaps with BioAffinity's non-invasive diagnostic approaches for cancer detection.
Fulgent Genetics
FLGT
Mkt Cap539.57M
Fulgent Genetics, Inc. offers comprehensive genetic testing, in direct competition with BioAffinity's focus on early disease detection through biomarker analysis.
QuidelOrtho
QDEL
Mkt Cap1.01B
QuidelOrtho Corporation is involved in diagnostic healthcare, including cancer diagnostics, making it a competitor in the rapid diagnostic market.
Myriad Genetics
MYGN
Mkt Cap302.25M
Myriad Genetics, Inc. specializes in genetic testing and personalized medicine, competing in the same space as BioAffinity by offering diagnostic solutions for cancer.
Pacific Biosciences of California
PACB
Mkt Cap435.16M
Illumina
ILMN
Mkt Cap32.55B
Illumina, Inc. is a leading company in genomics and sequencing, which underpins the technological advancements in cancer diagnostics and research, indirectly competing with BioAffinity's approach to early detection and diagnosis.

About

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
Show more...
CEO
Maria Zannes
Employees
57
Country
United States
ISIN
US09076W4069

Listings

BOATS
BOATS
BIAF.BOATS
XNAS
US
BIAF
XNAS
US
BIAFW

0 Comments

Share your thoughts

FAQ

What is BioAffinity Technologies stock price today?▼
The current price of BIAF is $15.27 USD — it has increased by +19.48% in the past 24 hours. Watch BioAffinity Technologies stock price performance more closely on the chart.
What is BioAffinity Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange BioAffinity Technologies stocks are traded under the ticker BIAF.
Is BioAffinity Technologies stock price growing?▼
BIAF stock has risen by +213.55% compared to the previous week, the month change is a +2,781.13% rise, over the last year BioAffinity Technologies has showed a +112.97% increase.
What is BioAffinity Technologies market cap?▼
Today BioAffinity Technologies has the market capitalization of 9.04M
When is the next BioAffinity Technologies earnings date?▼
BioAffinity Technologies is going to release the next earnings report on November 18, 2026.
What were BioAffinity Technologies earnings last quarter?▼
BIAF earnings for the last quarter are -9.6 USD per share, whereas the estimation was -31.5 USD resulting in a +69.52% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is BioAffinity Technologies revenue for the last year?▼
BioAffinity Technologies revenue for the last year amounts to 6.16M USD.
What is BioAffinity Technologies net income for the last year?▼
BIAF net income for the last year is -14.91M USD.
How many employees does BioAffinity Technologies have?▼
As of September 06, 2026, the company has 57 employees.
In which sector is BioAffinity Technologies located?▼
BioAffinity Technologies operates in the Health & Wellness sector.
When did BioAffinity Technologies complete a stock split?▼
The last stock split for BioAffinity Technologies was on August 24, 2026 with a ratio of 1:15.
Where is BioAffinity Technologies headquartered?▼
BioAffinity Technologies is headquartered in SAN ANTONIO, United States.